Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer
Authors:
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1α,24‐dihydroxyvitamin D2The Prostate, 2003
- Inhibition of Nuclear Factor-κB by a Nitro-Derivative of Flurbiprofen: A Possible Mechanism for Antiinflammatory and Antiproliferative EffectAntioxidants & Redox Signaling, 2003
- A Population-Based Study of Daily Nonsteroidal Anti-inflammatory Drug Use and Prostate CancerMayo Clinic Proceedings, 2002
- SAFETY AND EFFICACY OF EXISULIND FOR TREATMENT OF RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMYJournal of Urology, 2001
- Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: Preliminary resultsSeminars in Oncology, 2001
- A Fully Synthetic Globo H Carbohydrate Vaccine Induces a Focused Humoral Response in Prostate Cancer Patients: A Proof of PrincipleAngewandte Chemie International Edition, 1999
- Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigenThe Prostate, 1996
- Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3Endocrinology, 1995
- Study of the expression and function of the tumour-associated antigen CaMBr1 in small cell lung carcinomasEuropean Journal of Cancer, 1993
- The Dendritic Cell System and its Role in ImmunogenicityAnnual Review of Immunology, 1991